Cryoport, Inc. (NASDAQ:CYRX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Cryoport, Inc. (NASDAQ:CYRX) have received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $12.29.

Several equities research analysts recently issued reports on CYRX shares. UBS Group raised their target price on shares of Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a report on Friday, October 18th. Roth Mkm dropped their price target on Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Finally, Guggenheim began coverage on Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective for the company.

Cryoport Stock Performance

Shares of NASDAQ CYRX opened at $7.80 on Friday. The firm’s 50-day moving average price is $7.44 and its 200-day moving average price is $7.95. Cryoport has a 52-week low of $5.32 and a 52-week high of $20.10. The company has a market cap of $385.56 million, a PE ratio of -2.31 and a beta of 1.62. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48.

Insider Transactions at Cryoport

In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total transaction of $54,972.74. Following the sale, the director now owns 59,497 shares in the company, valued at approximately $443,847.62. This trade represents a 11.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jerrell Shelton sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total transaction of $325,500.00. Following the completion of the transaction, the chief executive officer now owns 731,897 shares of the company’s stock, valued at approximately $4,764,649.47. The trade was a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 109,869 shares of company stock worth $735,673 in the last three months. Corporate insiders own 10.10% of the company’s stock.

Institutional Trading of Cryoport

Institutional investors and hedge funds have recently modified their holdings of the company. Fred Alger Management LLC raised its stake in Cryoport by 49.9% during the 3rd quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company’s stock valued at $21,887,000 after purchasing an additional 898,481 shares during the period. Massachusetts Financial Services Co. MA raised its position in shares of Cryoport by 2.6% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,035,586 shares of the company’s stock valued at $14,066,000 after buying an additional 52,103 shares during the last quarter. Thematics Asset Management lifted its holdings in shares of Cryoport by 176.2% in the third quarter. Thematics Asset Management now owns 1,705,000 shares of the company’s stock worth $13,828,000 after buying an additional 1,087,800 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Cryoport by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,097,369 shares of the company’s stock worth $8,902,000 after acquiring an additional 38,520 shares during the last quarter. Finally, State Street Corp grew its stake in Cryoport by 2.8% during the third quarter. State Street Corp now owns 1,003,080 shares of the company’s stock valued at $8,135,000 after acquiring an additional 27,438 shares in the last quarter. 92.90% of the stock is currently owned by institutional investors.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.